Globeflex Capital L P maintained its stake in Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,012 shares of the specialty pharmaceutical company’s stock at the close of the 2nd quarter. Globeflex Capital L P owned about 0.18% of Juniper Pharmaceuticals worth $101,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNP. AWM Investment Company Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $475,000. Renaissance Technologies LLC lifted its stake in shares of Juniper Pharmaceuticals by 21.7% in the 1st quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock worth $1,470,000 after acquiring an additional 55,200 shares during the period. KCG Holdings Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $112,000. Goldman Sachs Group Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $100,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Juniper Pharmaceuticals by 2.3% in the 2nd quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock worth $211,000 after acquiring an additional 941 shares during the period. 36.20% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.watchlistnews.com/globeflex-capital-l-p-maintains-stake-in-juniper-pharmaceuticals-inc-jnp/1600573.html.

JNP has been the subject of a number of research analyst reports. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $31.00 to $34.00 in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Juniper Pharmaceuticals presently has an average rating of “Buy” and an average price target of $23.00.

Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) opened at 4.55 on Friday. Juniper Pharmaceuticals, Inc. has a 52 week low of $3.65 and a 52 week high of $6.40. The stock has a 50 day moving average of $4.56 and a 200-day moving average of $4.63. The firm has a market capitalization of $49.34 million, a price-to-earnings ratio of 5.88 and a beta of 0.22.

Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.10. The firm had revenue of $13.96 million during the quarter, compared to analysts’ expectations of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. Analysts expect that Juniper Pharmaceuticals, Inc. will post ($0.46) earnings per share for the current year.

Juniper Pharmaceuticals Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Institutional Ownership by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.